Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725742 | 1.00 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL727346 | 0.90 | HDAC1 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL727345 | 0.90 | HDAC1 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL725023 | 0.86 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL725022 | 0.86 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL725500 | 0.84 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL725501 | 0.84 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL727133 | 0.79 | — | — | |
| SCHEMBL727132 | 0.79 | — | — | |
| SCHEMBL1093274 | 0.78 | NOD2 (0.47) | NOD2TDP1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4803935-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | claimed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | claimed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2579863-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | Affinium Pharmaceuticals, Inc. (CA) | 2013-04-17 | — | — | EP | disclosed |
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7790716-B2 | fatty acid biosynthesis inhibitors such as E)-3-(6-aminopyridin-3-yl)-N-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)acrylamide, used fro the treatment of bacterial infections; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090275572-A1 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557125-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-07-07 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | HDAC3 804/4885HDAC4 1047/4885HDAC1 87/4885 |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | HDAC3 535/4885HDAC4 560/4885HDAC1 488/4885 |
| US-20090275572-A1 | FAB I INHIBITORS | SERPINB1, TFPI, TFPI2 | HDAC3 804/4885HDAC4 1047/4885HDAC1 87/4885 |
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | HDAC3 804/4885HDAC4 1047/4885HDAC1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.